ATN1: A Drug Target / Disease Biomarker (G1822)

Target Name: ATN1

NCBI ID: G1822

ATN1

ATN1: A Drug Target / Disease Biomarker

ATN1, also known as interleukin-18 (IL-18), is a protein that is expressed in various tissues throughout the body. It is a cytokine that plays a crucial role in the immune system, where it helps to regulate and coordinate the immune response. ATN1 is also involved in inflammation, fibrosis, and other pathological processes.

Due to its involvement in a wide range of biological processes, ATN1 has been identified as a potential drug target. Researchers are actively searching for small molecules that can modulate ATN1 activity and have developed a number of lead compounds that are currently in development. In this article, we will explore the biology of ATN1 and its potential as a drug target.

The biology of ATN1

ATN1 was first identified in the 1980s as a cytokine that was expressed in various tissues, including the liver, spleen, and peripheral blood cells. It is a member of the IL-1 family of cytokines, which include IL-1, IL-2, and IL-3. These cytokines are involved in the regulation of immune responses, as well as other cellular processes, such as cell growth, differentiation, and survival.

ATN1 is involved in the regulation of both cell-cell and cell-tissue interactions. It has been shown to play a role in the regulation of T cell development and function, as well as the regulation of inflammation. ATN1 has also been shown to be involved in the regulation of fibrosis, which is the excessive growth and development of connective tissue that can lead to the development of diseases such as cancer, heart disease, and diabetes.

In addition to its role in inflammation and fibrosis, ATN1 is also involved in the regulation of cellular processes that are important for tissue repair and regeneration. It has been shown to play a role in the regulation of cell proliferation, apoptosis (programmed cell death), and the production of matrix proteins, which are important for tissue repair and regeneration.

The potential drug targets for ATN1

The potential drug targets for ATN1 are vast and varied. Because of its involvement in a wide range of biological processes, ATN1 is a prime candidate for targeting with small molecules. Some potential drug targets for ATN1 include:

1. Modulation of ATN1 signaling: One of the potential drug targets for ATN1 is the modulation of its signaling pathway. This can be achieved through the use of small molecules that act on the ATN1 receptor, which is a G protein-coupled receptor. By modulating the activity of the ATN1 receptor, small molecules can alter the levels of ATN1 in the cell and potentially disrupt its signaling pathway.
2. inhibition of ATN1-mediated inflammation: ATN1 has been shown to play a role in the regulation of inflammatory responses. Small molecules that inhibit ATN1 signaling may have potential as anti-inflammatory drugs.
3. modulation of ATN1-mediated fibrosis: ATN1 has been shown to play a role in the regulation of fibrosis, which is the excessive growth and development of connective tissue. Small molecules that modulate ATN1 signaling may have potential as fibrosis drugs.
4. modulation of ATN1-mediated tissue repair and regeneration: ATN1 has been shown to play a role in the regulation of cellular processes that are important for tissue repair and regeneration. Small molecules that modulate ATN1 signaling may have potential as tissue repair and regeneration drugs.

Currently in development

There are a number of small molecules that are being developed as potential drugs for ATN1. These molecules range from inhibitors of ATN1 signaling to modulators of ATN1-mediated signaling pathways. Some examples of these drugs include:

1. canakinumab: Canakinumab is an anti-inflammatory drug that is being developed as a potential treatment for a variety of

Protein Name: Atrophin 1

Functions: Transcriptional corepressor. Recruits NR2E1 to repress transcription. Promotes vascular smooth cell (VSMC) migration and orientation (By similarity). Corepressor of MTG8 transcriptional repression. Has some intrinsic repression activity which is independent of the number of poly-Gln (polyQ) repeats

The "ATN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets